PRTA

Over the past six months, Prothena's stock price was impacted by several events. In October 2026, a development chief resigned to join a strategic partner. In September 2026, Prothena announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, and insider buying was reported, including a 10% owner's spouse buying 162,000 shares and Manatee Equity Fund buying 103,500 shares. In August 2026, the company reported its Second Quarter 2026 Financial Results and Business Highlights, which saw a +2.10% stock price increase. In May 2026, Prothena reported its First Quarter 2026 Financial Results and Business Highlights, leading to a +2.00% stock price increase; during this quarter, Novo Nordisk paid Prothena a $50 million clinical milestone payment for coramitug, and Prothena initiated a share repurchase program for up to $100 million for 2026. The stock experienced a 1-year change of -16.3% and a 1-month change of -13.7%, declining by 10.04% from September 30, 2025, to September 29, 2026, with its price fluctuating between a low of $7.73 and a high of $11.80 over the last year.